Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adu…

Detailed price information for Milestone Pharmaceuticals Inc (MIST-Q) from The Globe and Mail including charting and trades.
Monthly Prescribing Reference

Cardamyst Nasal Spray Now Available for Self-Treatment of PSVT Episodes

Credit: Milestone Pharmaceuticals. Each nasal spray device delivers 2 sprays containing a total of etripamil 70mg. The intranasal therapy consists of a novel calcium channel blocker and is designed to ...
Investing

Milestone’s PSVT treatment CARDAMYST now available in US pharmacies

MONTREAL/CHARLOTTE - Milestone Pharmaceuticals Inc. (NASDAQ:MIST) announced Monday that its recently approved CARDAMYST (etripamil) nasal spray is now available through U.S. retail pharmacies for ...
Nasdaq

Milestone Launches CARDAMYST, First Self-Administered FDA-Approved PSVT Therapy

(RTTNews) - Milestone Pharmaceuticals Inc. (MIST) announced that CARDAMYST, the first and only FDA-approved self-administered treatment for adults with paroxysmal supraventricular tachycardia, is now ...

Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST (etripamil) Nasal Spray, the First and Only FDA-Approve…

CARDAMYST is now conveniently available to patients through retail pharmaciesNational sales force hired with promotional ...

Milestone Launches CARDAMYST Nasal Spray in U.S. Pharmacies

Detailed price information for Milestone Pharmaceuticals Inc (MIST-Q) from The Globe and Mail including charting and trades.

Milestone Pharmaceuticals announces U.S. availability of cardamyst

Milestone Pharmaceuticals (MIST) announced that cardamyst nasal spray, its first commercial product, is now available through ...